Physician profile
Ming Zhou
NPI 1619933850
$10,862.12
in general payments reported to CMS, 2019-2025
34 companies · $3,493 in 2025
The $3,493 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,674 · 2020: $580 · 2021: $1,200 · 2022: $1,149 · 2023: $734 · 2024: $1,033 · 2025: $3,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,300 · Food and Beverage: $1,702 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,300.00 |
| Food and Beverage | $1,701.76 |
| Education | $258.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,152.31 | 2019-2025 | Calquence, Datroway, Lynparza |
| Amgen INC. | $703.12 | 2019-2024 | Lumakras |
| Janssen Biotech, INC. | $565.22 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| Genentech USA, INC. | $548.17 | 2019-2024 | Polivy |
| Lilly USA, LLC | $482.14 | 2019-2023 | |
| Daiichi Sankyo INC. | $326.80 | 2021-2024 | Enhertu |
| Kite Pharma, INC. | $308.02 | 2019-2022 | |
| Astellas Pharma US INC | $299.98 | 2019-2022 | |
| Seagen INC. | $289.63 | 2020-2023 | |
| Pfizer INC. | $287.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $250.00 | 2021-2022 | |
| Incyte Corporation | $214.99 | 2021-2024 | |
| Eisai INC. | $213.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $197.56 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $194.27 | 2020-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $178.88 | 2022-2023 | Keytruda |
| Gilead Sciences, INC. | $139.26 | 2019-2024 | Vemlidy |
| Abbvie INC. | $114.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.08 | 2019 | |
| Stemline Therapeutics INC. | $110.53 | 2024 | Orserdu |
| Tesaro, INC. | $104.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $102.85 | 2019 | |
| Rigel Pharmaceuticals, INC. | $100.96 | 2023 | Tavalisse, Rezlidhia |
| Celgene Corporation | $94.51 | 2019 | |
| Puma Biotechnology, INC. | $91.35 | 2019 | |
| Foundation Medicine, INC. | $91.27 | 2020 | |
| Karyopharm Therapeutics INC. | $86.82 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $83.70 | 2019-2021 | |
| Acrotech Biopharma INC. | $77.70 | 2021-2022 | |
| Advanced Accelerator Applications | $56.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.95 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.81 | 2021 | |
| Smith+Nephew, INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.